Page 153 - NobleCon21

Silexion Therapeutics Corp

SELECTED FINANCIAL ITEMS SLXN
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.63) (1.25) 8.04 (23.24) (24.09)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (8.54) (1.42) 11.86 (31.29) (29.39)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 5.26 3.59 3.09 2.86 2.86
Cash & Short Term Investments 4.60 2.78 1.97 1.19 1.19
% of Assets 87% 78% 64% 41% 41%
Current Assets -Total 4.98 3.34 3.05 2.25 2.25
% of Assets 95% 93% 99% 79% 79%
Total Liabilities 2.26 1.98 7.67 6.85 6.85
% of Assets 43% 55% 248% 239% 239%
Current Liabilities - Total 2.20 1.94 3.58 3.52 3.52
% of Assets 42% 54% 116% 123% 123%
Long Term Debt NA NA NA 2.96 2.96
% of Assets NM NM NM 103% 103%
Total Equity 3.00 1.61 (4.58) (3.99) (3.99)
% of Assets 57% 45% -148% -139% -139%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.26) (1.75) (2.65) (2.93) (8.59)
Net Cash Flow - Investing (0.00) (0.01) (0.02) 0.00 (0.03)
Net Cash Flow - Financing 0.00 NA 2.92 2.18 5.10

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference